Breakthrough T1d (Formerly Known as Jdrf Intl.)
Based in DC
AI Overview
With $6.5M in lobbying spend across 33 quarterly filings, Breakthrough T1d (Formerly Known as Jdrf Intl.) is one of the biggest lobbying spenders in Washington. Their lobbying covers 4 issue areas. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $1.2M |
| 2019 | $1.3M |
| 2020 | $430K |
| 2021 | $230K |
| 2022 | $340K |
| 2023 | $1.2M |
| 2024 | $820K |
| 2025 | $940K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Breakthrough T1d (Formerly Known as Jdrf Intl.) disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Budget/Appropriations, Taxation, Small Business
H.R. 3917 - To amend the Public Health Service Act to extend funding for the Special Diabetes Program for Indians
H.R. 3924 - To amend the Public Health Service Act to extend funding for the Special D
H.R. 3268, H. Rept. 115-232 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
S. 1603, S. Rept. 115-131 Agriculture, Rural Development,
Issues related to the use of smart technology in collaboration with devices for the management
of type 1 diabetes (T1D).
Issues related to drug pricing, specifically as it relates to Insulin.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.